# Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
Canonical URL: https://biopharmsignal.com/news/ANAB/anaptys-files-motion-to-dismiss-tesaro-s-claim-of-anticipatory-breach-of-contract-in-ongoing-litigation-against-tesaro-a-gsk-subsidiary
Ticker: ANAB
Company: AnaptysBio, Inc.
Source: AnaptysBio, Inc.
Published: 2026-01-08 23:00 EST
Original Source URL: https://ir.anaptysbio.com
## Summary

Trial to resolve all claims in the Anaptys and Tesaro /GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO , Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion

## Article Body
Trial to resolve all claims in the Anaptys and Tesaro /GSK dispute is scheduled for July 14-17, 2026 SAN DIEGO , Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion
## Recent Company News
- 2026-05-12 20:15 EST — [Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ANAB/anaptys-announces-first-quarter-2026-financial-results-and-provides-business-update) — Source: AnaptysBio, Inc.
- 2026-05-11 13:15 EST — [Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors](https://biopharmsignal.com/news/ANAB/anaptys-appoints-chris-murphy-as-chief-financial-officer-and-owen-hughes-to-board-of-directors) — Source: AnaptysBio, Inc.
- 2026-05-04 20:15 EST — [Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference](https://biopharmsignal.com/news/ANAB/anaptys-to-participate-at-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference) — Source: AnaptysBio, Inc.
- 2026-04-24 19:40 EST — [Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim](https://biopharmsignal.com/news/ANAB/delaware-chancery-court-rules-in-favor-of-anaptys-by-dismissing-tesaro-s-anticipatory-breach-claim) — Source: AnaptysBio, Inc.
- 2026-04-20 13:15 EST — [Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations](https://biopharmsignal.com/news/ANAB/anaptys-completes-separation-of-first-tracks-biotherapeutics-and-now-exclusively-manages-gsk-and-vanda-financial-collaborations) — Source: AnaptysBio, Inc.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)